Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine whether oral ENMD-2076 is effective in treatment of patients with platinum resistant ovarian, fallopian, or peritoneal cancer. Additional sites to be added.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
CASI Pharmaceuticals, Inc.
NCT06188520 · ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)
NCT06840886 · Advanced Solid Tumors, Ovarian Cancer, and more
NCT07432633 · Colorectal Cancer, Epithelial Ovarian Cancer, and more
NCT07144826 · Advanced Ovarian Carcinoma, Recurrent Ovarian Carcinoma, and more
NCT05364879 · Prehabilitation, Exercise, and more
University of Colorado Cancer Center
Aurora, Colorado
University of Chicago Medical Center
Chicago, Illinois
Indiana University Simon Cancer Center
Indianapolis, Indiana
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions